Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registryResearch in context [PDF]
EClinicalMedicine, 2023 Summary: Background: Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients with COVID-19, but data on efficacy in patients with haematological malignancy are scarce. Here, we describe the outcome of nirmatrelvir/
Jon Salmanton-García +115 more
doaj +13 more sources
A Phase 1 Multiple‐Dose, Open‐Label, Pharmacokinetic Study of Nirmatrelvir/Ritonavir in Healthy Lactating Women [PDF]
Clinical and Translational ScienceIn accordance with the Centers for Disease Control and Prevention recommendations, pregnant women and those with a recent pregnancy (i.e., lactating) are considered at high risk of developing severe COVID‐19 and qualify for treatment with nirmatrelvir ...
Jacqueline Gerhart +7 more
doaj +3 more sources
Effectiveness and Safety of Simnotrelvir/Ritonavir and Nirmatrelvir/Ritonavir in the Treatment of Moderate to Severe COVID‐19 [PDF]
Immunity, Inflammation and DiseaseBackground and Aim Simnotrelvir/ritonavir and nirmatrelvir/ritonavir are major treatments for COVID‐19, but their comparative efficacy and safety, especially in patients with moderate to severe COVID‐19, remain unclear.
Xin Chen +7 more
doaj +3 more sources
BMC Nephrology, 2023 Background Despite vaccination coronavirus disease 2019 (COVID-19)-associated mortality caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains high in kidney transplant recipients.
Johanna Schneider +5 more
doaj +2 more sources
Safety, Pharmacokinetics, and Dose Recommendations for Nirmatrelvir/Ritonavir in Individuals with Mild to Moderate COVID-19 and Severe Renal Impairment. [PDF]
Clin Pharmacol TherPatients with severe renal impairment and COVID‐19 are at high risk for severe disease and death. Nirmatrelvir/ritonavir, an antiviral therapy for COVID‐19, is eliminated by renal excretion and can accumulate in patients with severe renal impairment.
Gerhart J +7 more
europepmc +2 more sources
Effectiveness and safety of azvudine versus nirmatrelvir/ritonavir in hospitalized patients with COVID-19 [PDF]
BMC Infectious DiseasesPurpose To compare the effectiveness and safety of two antiviral drugs, azvudine and nirmatrelvir/ritonavir, in treating hospitalized patients with COVID-19.
Jin Yang +6 more
doaj +3 more sources
Nirmatrelvir/ritonavir reduced mortality in severe or critical COVID-19 patients: a multicenter retrospective cohort study [PDF]
Frontiers in MedicineBackgroundPatients with severe or critical coronavirus disease 2019 (COVID-19) remain at a high risk of mortality. Although nirmatrelvir/ritonavir has demonstrated efficacy in non-severe COVID-19 patients with high-risk factors, its effectiveness in ...
Heng Zhao +11 more
doaj +2 more sources
Prevalence of potentially inappropriate use of antiviral therapy with simnotrelvir-ritonavir versus nirmatrelvir-ritonavir in hospitalised patients: a retrospective study in Beijing, China [PDF]
BMJ Open Respiratory ResearchBackground While simnotrelvir-ritonavir and nirmatrelvir-ritonavir, the oral antiviral agents targeting the 3C-like proteases, are widely used in China, robust data on their appropriate use remain limited in hospitalised patients.
Hui Zhang +9 more
doaj +2 more sources
Effectiveness comparison of nirmatrelvir/ritonavir versus molnupiravir in COVID-19 patients with comorbidities in Taiwan: a multi-centre electronic health record study [PDF]
BMC Infectious DiseasesBackground COVID-19 patients frequently present with various comorbidities. Two developed antiviral medications, nirmatrelvir/ritonavir and molnupiravir, have been utilized in COVID-19 patients; but comparisons of the effectiveness between nirmatrelvir ...
Wen-Kuang Lin +17 more
doaj +2 more sources
Drug-related problems and challenges encountered by pharmacists in nirmatrelvir/ritonavir counselling during the covid-19 pandemic: a multi-center study [PDF]
Scientific ReportsPharmacists’ counselling roles expanded significantly during the COVID-19 pandemic, yet drug-related problems (DRPs) and challenges during nirmatrelvir/ritonavir counselling remain underreported.
Shamala Balan +20 more
doaj +2 more sources